ADMS - Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect Affimed Down On Clinical Hold

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study

Adamas Pharma (ADMS) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths were probably unrelated and rather normal in this highly sick patient population, and the other drug is probably not a direct competition and not as good as GOCOVRI in certain aspects, such excuses have not helped the stock. It has continued to slide all the way to 52-week lows